Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Iran-Israel Missile Strikes Continue Amid Mixed Signals on U.S.-Iran Diplomacy 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
9 Tips for Avoiding Tax Season Cyber Scams 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
